For practical treatment using PD-1 or PD-L1 inhibitors in TNBC, serious adverse events, such as serious pneumonitis, hypothyroidism, ALT elevation, and adrenal insufficiency, should be considered and monitored. The gene discussed is PDCD1; the disease is hypothyroidism.